



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/19, C07K 14/52, C12N 15/11, A61K 38/19, G01N 33/68, C12Q 1/68, C12N 1/21, C07K 16/24, A61K 39/395		A1	(11) International Publication Number: WO 96/25497 (43) International Publication Date: 22 August 1996 (22.08.96)
(21) International Application Number: PCT/US96/02225 (22) International Filing Date: 16 February 1996 (16.02.96) (30) Priority Data: 08/390,740 17 February 1995 (17.02.95) US (71) Applicant: INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors: COLEMAN, Roger, 260 Mariposa, #2, Mountain View, CA 94041 (US). BANDMAN, Olga; 2309 Rock Street, #27, Mountain View, CA 94043 (US). WILDE, Craig, G.; 1239 Mandarin Drive, Sunnyvale, CA 94087 (US). (74) Agents: LUTHER, Barbara, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: NEW CHEMOKINES EXPRESSED IN PANCREAS

```

5' ATG AAG GTC TCC GCA GCA CTT CTG TGG CTG CTC ATA GCA GCT GCC TTC AGC
   M  K  V  S  A  A  L  L  W  L  L  L  I  A  A  A  F  S
      58      67      76      85      94      103
CCC CAG GGG CTC ACT GGG CCA GCT TCT GTC CCA ACC ACC TGC TGC TTT AAC CTG
P  Q  G  L  T  G  P  A  S  V  P  T  T  C  C  F  N  L
      112     121     130     139     148     157
GCC AAT AGG AAG ATA CCC CTT CAG CCA CTA GAG AGC TAC AGG AGA ATC ACC AGT
A  N  R  K  I  P  L  Q  R  L  E  S  Y  R  R  I  T  S
      166     175     184     193     202     211
GGC AAA TGT CCC CAG AAA GCT GTG ATC TTC AAG ACC AAA CTG GCC AAG GAT ATC
G  K  C  P  Q  K  A  V  I  F  K  T  K  L  A  K  D  I
      220     229     238     247     256     265
TGT GCC GAC CCC AAG AAG AAG TGG GTG CAG GAT TCC ATG AAG TAT CTG GAC CAA
C  A  D  P  K  K  K  W  V  Q  D  S  M  K  Y  L  D  Q
      274     283     292     301     310     319
AAA TCT CCA ACT CCA AAG CCA 3'
K  S  P  T  P  K  P

```

(57) Abstract

The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2- encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2- encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NEW CHEMOKINES EXPRESSED IN PANCREAS

BACKGROUND ART

5 The pancreas is an elongated organ which lies behind and below the stomach and consists of both exocrine and endocrine tissues. In descending order, the exocrine portion is divided into lobes, lobules, and functional secretory units known as acini. All acini eventually drain into the main pancreatic duct which joins the bile duct from the liver before it empties
10 into the duodenum. Acinar cells comprise 80% of the pancreas and secrete enzymes in either inactive or active form which assist digestion. Epithelial cells of the ductules secrete large amounts of bicarbonate ions and water which neutralize acidic chyme as it leaves the stomach and enters the duodenum as well as the enzymes for digesting protein, carbohydrates,
15 and fats.

The most important and abundant proteolytic enzymes are trypsin, chymotrypsin, and carboxypeptidase. The serine proteases, trypsin and chymotrypsin, split whole and partially-digested proteins into polypeptides of different sizes; then, carboxypeptidase breaks down the polypeptides into
20 individual amino acids. Several elastases, which are also serine proteases, and nucleases, which digest nucleic acids, are also found in the pancreatic juice.

The principal enzyme for digesting carbohydrates in the gut is pancreatic amylase. It hydrolyzes starches, glycogen, and most other non-
25 cellulosic carbohydrates to form disaccharides and trisaccharides. The main enzymes for fat digestion are pancreatic lipase, cholesterol esterase, and phospholipase. Pancreatic lipase hydrolyzes neutral fat into fatty acids and monoglycerides. Cholesterol esterase hydrolyzes cholesterol esters, and phospholipase removes fatty acid molecules from phospholipids.

30 The four molecules which control acinar secretion are acetylcholine and the hormones, gastrin, cholecystokinin (CCK), and secretin. Acetylcholine is released from the parasympathetic vagus and other cholinergic nerve endings, gastrin is secreted by cells of the stomach, and CCK and secretin are secreted by the upper small intestine. The
35 gastrointestinal (GI) hormones are absorbed into the blood and transported to the pancreas where they stimulate acini to secrete enzymes and ductal cells to secrete the sodium bicarbonate and water which washes the pancreatic enzymes into the duodenum.

40 The endocrine pancreas consists of islets of Langerhans, whose cells are separated from the exocrine lobules and are distributed throughout the pancreas. The function of the various types of endocrine cells which make up the islets is to secrete the hormones which participate in the metabolism

of proteins, carbohydrates, and fats.

The major endocrine cells are α , β , and δ cells; the minor cells are C cells, EC cells, and PP cells. About 15% of the islet cell population are α cells which are located along the periphery of islets and secrete the hormone glucagon. β cells comprise about 70% of the islet cell population, are located around the center of the islets, and secrete the hormone insulin. δ cells comprise about 10% of the population, are located close to α cells and secrete two different hormones, somatostatin and vasoactive intestinal peptide (VIP). C, EC, and PP cells make up the final 5% of the islet cell population. The function of C cells is unknown, but EC and PP cells secrete serotonin and pancreatic polypeptide, respectively.

Inflammation of the pancreas or pancreatitis may be classified as either acute or chronic by clinical criteria. With treatment, acute pancreatitis can often be cured and normal function restored. Chronic pancreatitis often results in permanent damage. The precise mechanisms which trigger acute inflammation are not understood. However, some causes in the order of their importance are alcohol ingestion, biliary tract disease, post-operative trauma, and hereditary pancreatitis. One theory provides that autodigestion, the premature activation of proteolytic enzymes in the pancreas rather than in the duodenum, causes acute pancreatitis. Any number of other factors including endotoxins, exotoxins, viral infections, ischemia, anoxia, and direct trauma may activate the proenzymes. In addition any internal or external blockage of pancreatic ducts can also cause an accumulation of pancreatic juices in the pancreas resulting in cellular damage.

As is the case in inflammation of other tissues, leukocytes including monocytes, macrophages, basophils, and eosinophils infiltrate the inflamed area of the pancreas. Their primary role is to clean up the site of the inflammation; however, macrophages may produce powerful oxidants and proteases which contribute to tissue destruction. Leukocytes also secrete a range of cytokines which recruit other cells to the area.

The investigation of the critical, regulatory processes by which white cells proceed to their appropriate destination and interact with other cells is underway. The current model of leukocyte movement or trafficking from the blood to injured or inflamed tissues comprises the following steps. The first step is the rolling adhesion of the leukocyte along the endothelial cells of the blood vessel wall. This movement is mediated by transient interactions between selectins and their ligands. A second step involves cell activation which promotes a more stable leukocyte-endothelial cell interaction mediated by the integrins and their ligands. This stronger, more stable adhesion precipitates the final steps--leukocyte diapedesis and

extravasation into the tissues.

The chemokine family of polypeptide cytokines possesses the cellular specificity required to explain leukocyte trafficking in different abnormal, inflammatory or diseased situations. First, chemokines mediate the expression of particular adhesion molecules on endothelial cells; and second, they generate gradients of chemoattractant factors which activate specific cell types. In addition, the chemokines stimulate the proliferation of specific cell types and regulate the activation of cells which bear specific receptors. These activities demonstrate a high degree of target cell specificity.

The chemokines are small polypeptides, generally about 70-100 amino acids (aa) in length, 8-11 kD in molecular weight and active over a 1-100 ng/ml concentration range. Initially, they were isolated and purified from inflamed tissues and characterized relative to their bioactivity. More recently, chemokines have been discovered through molecular cloning techniques and characterized by structural as well as functional analysis.

The chemokines are related through a four-cysteine motif which is based primarily on the spacing of the first two cysteine residues in the mature molecule. Currently the chemokines are assigned to one of two families, the C-C chemokines (α) and the C-X-C chemokines (β). Although exceptions exist, the C-X-C chemokines generally activate neutrophils and fibroblasts while the C-C chemokines act on a more diverse group of target cells which include monocytes/macrophages, basophils, eosinophils, T lymphocytes and others. The known chemokines of both families are synthesized by many diverse cell types as reviewed in Thomson A. (1994) The Cytokine Handbook, 2d Ed. Academic Press, NY. The two groups of chemokines will be described in turn.

At this time, relatively few C-C chemokines have been described, and they appear to have less N-terminal processing than the C-X-C chemokines. A brief description of the known human (and/or murine) C-C chemokines follows. The macrophage inflammatory proteins alpha and beta (MIP-1 α and β) were first purified from stimulated mouse macrophage cell line and elicited an inflammatory response when injected into normal tissues. At least three distinct and non-allelic genes encode human MIP-1 α , and seven distinct genes encode MIP-1 β .

MIP-1 α and MIP-1 β consist of 68-69 aa which are about 70% identical in their acidic, mature secreted forms. They are both expressed in stimulated T cells, B cells and monocytes in response to mitogens, anti-CD3 and endotoxin, and both polypeptides bind heparin. While both molecules stimulate monocytes, MIP-1 α chemoattracts the CD-8 subset of T lymphocytes

and eosinophils, while MIP-1 β chemoattracts the CD-4 subset of T lymphocytes. In mouse, these proteins are known to stimulate myelopoiesis.

I-309 was cloned from a human γ - δ T cell line and shows 42% aa identity to T cell activation gene 3 (TCA3) cloned from mouse. There is
5 considerable nucleotide homology between the 5' flanking regions of these two proteins, and they share an extra pair of cysteine residues not found in other chemokines. Such similarities suggest I-309 and TCA3 are species homologs which have diverged over time in both sequence and function.

RANTES is another C-C chemokine which is expressed in T cells (but not
10 B cells), in platelets, in some tumor cell lines, and in stimulated rheumatoid synovial fibroblasts. In the latter, it is regulated by interleukins-1 and -4, transforming nerve factor and interferon- γ . The cDNA cloned from T cells encodes a basic 8 kD protein which lacks N-linked glycosylation and is able to affect lymphocytes, monocytes, basophils and
15 eosinophils. The expression of RANTES mRNA is substantially reduced following T cell stimulation.

Monocyte chemotactic protein (MCP-1) is a 76 aa protein which appears to be expressed in almost all cells and tissues upon stimulation by a variety of agents. The targets of MCP-1, however, are limited to monocytes
20 and basophils in which it induces a MCP-1 receptor:G protein-linked calcium flux (Charo I, personal communication). Two other related proteins (MCP-2 and MCP-3) were purified from a human osteosarcoma cell line. MCP-2 and MCP-3 have 62% and 73% aa identity, respectively, with MCP-1 and share its chemoattractant specificity for monocytes.

Current techniques for diagnosis of abnormalities in the inflamed or
25 diseased tissues mainly rely on observation of clinical symptoms or serological analyses of body tissues or fluids for hormones, polypeptides or various metabolites. Patients often manifest no clinical symptoms at early stages of disease or tumor development. Furthermore, serological analyses
30 do not always differentiate between invasive diseases and genetic syndromes which have overlapping or very similar ranges. Thus, development of new diagnostic techniques comprising small molecules such as the expressed chemokines are important to provide for early and accurate diagnoses, to give a better understanding of molecular pathogenesis, and to use in the
35 development of effective therapies.

The pancreas is reviewed in Guyton AC (1991) Textbook of Medical Physiology, WB Saunders Co, Philadelphia; and The Merck Manual of Diagnosis and Therapy, (1992) Merck Research Laboratories, Rahway, NJ. The chemokine molecules are reviewed in Schall TJ (1994) Chemotactic Cytokines: Targets
40 for Therapeutic Development. International Business Communications, Southborough, MA, pp 180-270; and in Paul WE (1993) Fundamental Immunology,

Raven Press, New York City (NYC), pp 822-826.

DISCLOSURE OF INVENTION

The subject invention provides nucleotide sequences which uniquely encode two novel human pancreatic proteins. The new genes, which are known as pancreatic expressed chemokines, or panec-1 and panec-2 (Incyte Clones 223187 and 226152), encode polypeptides designated PANEK-1 and PANEK-2, of the C-C chemokine family.

The invention also comprises diagnostic tests for physiologic or pathologic compromise of the pancreas which include the steps of testing a sample or an extract thereof with panec-1 or panec-2 DNA, fragments or oligomers thereof. Aspects of the invention include the antisense DNAs of panec-1 and panec-2; cloning or expression vectors containing panec-1 or panec-2; host cells or organisms transformed with expression vectors containing panec-1 or panec-2; a method for the production and recovery of purified PANEK-1 or PANEK-2 from host cells; and purified proteins, PANEK-1 and PANEK-2.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 displays the nucleotide sequence for panec-1 and the predicted amino acid (aa) sequence of the pancreas expressed chemokine, PANEK-1.

Figure 2 displays the nucleotide sequence for panec-2 and the predicted amino acid (aa) sequence of the pancreas expressed chemokine, PANEK-2.

Figure 3 shows the aa alignment of PANEK-1 and PANEK-2 with other human chemokines of the C-C family. Alignments shown were produced using the multisequence alignment program of DNASTAR software (DNASTAR Inc, Madison WI).

Figure 4 displays an analysis of PANEK-1 hydrophobicity based on the predicted aa sequence and composition.

Figure 5 displays an analysis of PANEK-2 hydrophobicity based on the predicted aa sequence and composition.

Figure 6 shows a relatedness tree of human C-C chemokines. The phylogenetic tree was generated by phylogenetic tree program of DNASTAR software (DNASTAR Inc, Madison WI) using the Clustal method with the PAM250 residue weight table.

MODES FOR CARRYING OUT THE INVENTION

Definitions

As used herein, "pancreas expressed chemokines" or PANEKs, refers to polypeptides, naturally occurring PANEKs or active fragments thereof, which are encoded by mRNAs transcribed from the cDNAs of SEQ ID NO: 1 and SEQ ID NO: 3.

"Active" refers to those forms of PANEC which retain the biologic and/or immunologic activities of any naturally occurring PANEC.

"Naturally occurring PANEC" refers to PANECs produced by human cells that have not been genetically engineered and specifically contemplates
5 various PANECs arising from post-translational modifications of the polypeptide including but not limited to acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

"Derivative" refers to polypeptides derived from naturally occurring PANECs by chemical modifications such as ubiquitination, labeling (e.g.,
10 with radionuclides, various enzymes, etc.), pegylation (derivatization with polyethylene glycol) or by insertion or substitution by chemical synthesis of aa such as ornithine, which do not normally occur in human proteins.

"Recombinant variant" refers to any polypeptide differing from naturally occurring PANECs by aa insertions, deletions, and substitutions,
15 created using recombinant DNA techniques. Guidance in determining which aa residues may be replaced, added or deleted without abolishing activities of interest, such as cell adhesion and chemotaxis, may be found by comparing the sequence of the particular PANEC with that of homologous cytokines and minimizing the number of aa sequence changes made in regions of high
20 homology.

Preferably, aa "substitutions" are the result of replacing one aa with another aa having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine, i.e., conservative aa replacements.
25 "Insertions" or "deletions" are typically in the range of about 1 to 5 aa. The variation allowed may be experimentally determined by systematically making insertions, deletions, or substitutions of aa in a PANEC molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.

30 Where desired, a "signal or leader sequence" can direct the polypeptide through the membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous protein sources by recombinant DNA techniques.

A polypeptide "fragment," "portion," or "segment" is a stretch of aa
35 residues of at least about 5 amino acids, often at least about 7 aa, typically at least about 9 to 13 aa, and, in various embodiments, at least about 17 or more aa. To be active, any PANEC polypeptide must have sufficient length to display biologic and/or immunologic activity.

An "oligonucleotide" or polynucleotide "fragment", "portion," or
40 "segment" is a stretch of nucleotide residues which is long enough to use in polymerase chain reaction (PCR) or various hybridization procedures to

amplify or simply reveal related parts of mRNA or DNA molecules.

The present invention includes purified PANEC-1 and PANEC-2 polypeptides from natural or recombinant sources, cells transformed with recombinant nucleic acid molecules encoding PANEC-1 and PANEC-2. Various methods for the isolation of the PANEC-1 and PANEC-2 polypeptides may be accomplished by procedures well known in the art. For example, such polypeptides may be purified by immunoaffinity chromatography by employing the antibodies provided by the present invention. Various other methods of protein purification well known in the art include those described in Deutscher M (1990) *Methods in Enzymology*, Vol 182, Academic Press, San Diego; and Scopes R (1982) *Protein Purification: Principles and Practice*. Springer-Verlag, New York City, both incorporated herein by reference.

"Recombinant" may also refer to a polynucleotide which encodes PANEC-1 or PANEC-2 and is prepared using recombinant DNA techniques. The DNAs which encode PANEC-1 and PANEC-2 may also include allelic or recombinant variants and mutants thereof.

"Oligonucleotides" or "nucleic acid probes" are prepared based on the cDNA sequences which encode PANEC-1 and PANEC-2 provided by the present invention. Oligonucleotides comprise portions of the DNA sequence having at least about 15 nucleotides, usually at least about 20 nucleotides. Nucleic acid probes comprise portions of the sequence having fewer nucleotides than about 6 kb, usually fewer than about 1 kb. After appropriate testing to eliminate false positives, these probes may be used to determine whether mRNAs encoding PANEC-1 and PANEC-2 are present in a cell or tissue or to isolate similar nucleic acid sequences from chromosomal DNA as described by Walsh PS et al (1992 *PCR Methods Appl* 1:241-250).

Probes may be derived from naturally occurring or recombinant single- or double-stranded nucleic acids or be chemically synthesized. They may be labeled by nick translation, Klenow fill-in reaction, PCR or other methods well known in the art. Probes of the present invention, their preparation and/or labeling are elaborated in Sambrook J et al (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, NY; or Ausubel FM et al (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, NYC, both incorporated herein by reference.

Alternatively, recombinant variants encoding these same or similar polypeptides may be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations may also be introduced to modify the properties of the polypeptide, to change

ligand-binding affinities, interchain affinities, or polypeptide degradation or turnover rate.

Detailed Description of the Invention

5 The present invention provides nucleotide sequences uniquely identifying novel chemokines of the C-C family, PANEC-1 and PANEC-2, which are highly expressed in the pancreas. Because PANEC-1 and PANEC-2 are specifically expressed in pancreas, the nucleic acids (panec1 and panec-2), polypeptides (PANEC-1 and PANEC-2) and antibodies to PANEC-1 and PANEC-2 are
10 useful in diagnostic assays based on chemokine production in cases of inflammation or disease affecting the pancreas. Excessive expression of either PANEC-1 or PANEC-2 can lead to activation of monocytes, macrophages, basophils, eosinophils, T lymphocytes and/or other cells which respond to the chemokines by producing abundant proteases and other molecules which can
15 lead to tissue damage or destruction. Therefore, a diagnostic test for excess expression of PANECs can accelerate diagnosis and proper treatment of an abnormal condition caused by viral or bacterial infections; mechanical injury associated with trauma; hereditary diseases affecting pancreatitis; biliary disease; infiltrative diseases such as leukemias and lymphomas; or
20 other physiologic and pathologic problems which affect the function of the organ.

 The nucleotide sequences encoding PANEC-1 and PANEC-2 (or their complement) have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as
25 hybridization probes, use as oligomers for PCR, use for chromosome and gene mapping, use in the recombinant production of PANEC-1 and PANEC-2, and use in generation of anti-sense DNA or RNA, their chemical analogs and the like. Uses of nucleotides encoding PANEC-1 and PANEC-2 disclosed herein are exemplary of known techniques and are not intended to limit their use in any
30 technique known to a person of ordinary skill in the art. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

35 It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of PANEC-encoding nucleotide sequences, some bearing minimal homology to the nucleotide sequence of any known and naturally occurring gene may be produced. The invention has specifically contemplated each and every possible variation of nucleotide
40 sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard

triplet genetic code as applied to the nucleotide sequence of naturally occurring PANECs, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode PANEC-1 and PANEC-2 and/or their variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring PANEC genes under stringent conditions, it may be advantageous to produce nucleotide sequences encoding PANEC-1 and PANEC-2 or their derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PANEC-1 and PANEC-2 and/or their derivatives without altering the encoded aa sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

Nucleotide sequences encoding PANEC-1 or PANEC-2 may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques (cf Sambrook J et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY). Useful nucleotide sequences for joining to panec include an assortment of cloning vectors, e.g., plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Vectors of interest include expression vectors, replication vectors, probe generation vectors, sequencing vectors, and the like. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for the host cell.

Another aspect of the subject invention is to provide for panec-1- or panec-2-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding PANEC-1 or PANEC-2. Such probes may also be used for the detection of similar chemokine encoding sequences and should preferably contain at least 50% of the nucleotides from a C-C encoding sequence. The hybridization probes of the subject invention may be derived from the nucleotide sequences of the SEQ ID NO 1 or SEQ ID NO 3 from genomic sequences including promoters, enhancer elements and introns of the respective naturally occurring panecs. Hybridization probes may be labeled by a variety of reporter groups, including radionuclides such as ³²P or ³⁵S, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

PCR as described US Patent Nos 4,683,195; 4,800,195; and 4,965,188 provides additional uses for oligonucleotides based upon the nucleotide

sequences which encode either PANEC-1 or PANEC-2. Such probes used in PCR may be of recombinant origin, may be chemically synthesized, or a mixture of both and comprise a discrete nucleotide sequence for diagnostic use or a degenerate pool of possible sequences for identification of closely related genomic sequences.

Other means of producing specific hybridization probes for panec DNAs include the cloning of nucleic acid sequences encoding PANEC-1 and PANEC-2 or PANEC-1 and PANEC-2 derivatives into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides.

It is now possible to produce a DNA sequence, or portions thereof, encoding PANEC-1 and PANEC-2 and their derivatives entirely by synthetic chemistry, after which the gene can be inserted into any of the many available DNA vectors using reagents, vectors and cells that are known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into the panec sequences or any portion thereof.

The nucleotide sequence can be used to construct an assay to detect inflammation or disease associated with abnormal levels of expression of PANEC-1 or PANEC-2. The nucleotide sequence can be labeled by methods known in the art and added to a fluid or tissue sample from a patient under hybridizing conditions. After an incubation period, the sample is washed with a compatible fluid which optionally contains a dye (or other label requiring a developer) if the nucleotide has been labeled with an enzyme. After the compatible fluid is rinsed off, the dye is quantitated and compared with a standard. If the amount of dye is significantly elevated, the nucleotide sequence has hybridized with the sample, and the assay indicates the presence of inflammation and/or disease.

The nucleotide sequence for panec-1 or panec-2 can be used to construct hybridization probes for mapping that gene. The nucleotide sequence provided herein may be mapped to a chromosome and specific regions of a chromosome using well known genetic and/or chromosomal mapping techniques. These techniques include in situ hybridization, linkage analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like. The technique of fluorescent in situ hybridization of chromosome spreads has been described, among other places, in Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, NYC.

Fluorescent in situ hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of Science (265:1981f). Correlation between the location of panec on a physical chromosomal map and a specific disease (or predisposition to a specific disease) can help delimit the region of DNA associated with that genetic disease. The nucleotide sequence of the subject invention may be used to detect differences in gene sequence between normal and carrier or affected individuals.

Nucleotide sequences encoding PANEC-1 and PANEC-2 may be used to produce purified PANEC-1 and PANEC-2 using well known methods of recombinant DNA technology. Among the many publications that teach methods for the expression of genes after they have been isolated is Goeddel (1990) Gene Expression Technology, Methods and Enzymology, Vol 185, Academic Press, San Diego. PANEC-1 and PANEC-2 may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from the same species in which panec nucleotide sequences are endogenous or from a different species. Advantages of producing PANEC-1 and PANEC-2 by recombinant DNA technology include obtaining adequate amounts of the protein for purification and the availability of simplified purification procedures.

Cells transformed with DNA encoding PANEC-1 or PANEC-2 may be cultured under conditions suitable for the expression of chemokines and recovery of the protein from the cell culture. PANEC-1 or PANEC-2 produced by a recombinant cell may be secreted or may be contained intracellularly, depending on the particular genetic construction used. In general, it is more convenient to prepare recombinant proteins in secreted form. Purification steps vary with the production process and the particular protein produced.

In addition to recombinant production, fragments of PANEC-1 or PANEC-2 may be produced by direct peptide synthesis using solid-phase techniques (cf Stewart et al (1969) Solid-Phase Peptide Synthesis, WH Freeman Co, San Francisco; Merrifield J (1963) J Am Chem Soc 85:2149-2154. In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Foster City, California) in accordance with the instructions provided by the manufacturer. Various fragments of PANEC-1 and PANEC-2 may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

PANEC-1 or PANEC-2 for antibody induction does not require biological activity; however, the protein must be immunogenic. Peptides used to induce specific antibodies may have an aa sequence consisting of at least five aa,

preferably at least 10 aa. They should mimic a portion of the aa sequence of the protein and may contain the entire aa sequence of a small naturally occurring molecules like PANEC-1 and PANEC-2. Short stretches of PANEC-1 or PANEC-2 aa may be fused with those of another protein such as keyhole limpet hemocyanin and the chimeric molecule used for antibody production.

Antibodies specific for PANEC-1 or PANEC-2 may be produced by inoculation of an appropriate animal with the polypeptide or an antigenic fragment. An antibody is specific for PANEC-1 or PANEC-2 if it is produced against an epitope of the polypeptide and binds to at least part of the natural or recombinant protein. Antibody production includes not only the stimulation of an immune response by injection into animals, but also analogous steps in the production of synthetic antibodies or other specific-binding molecules such as the screening of recombinant immunoglobulin libraries (cf Orlandi R et al (1989) PNAS 86:3833-3837, or Huse WD et al (1989) Science 256:1275-1281) or the in vitro stimulation of lymphocyte populations. Current technology (Winter G and Milstein C (1991) Nature 349:293-299) provides for a number of highly specific binding reagents based on the principles of antibody formation. These techniques may be adapted to produce molecules specifically binding PANECs.

An additional embodiment of the subject invention is the use of PANEC-1 or PANEC-2 specific antibodies, inhibitors, receptors or their analogs as bioactive agents to treat inflammation or disease of the pancreas including, but not limited to viral or bacterial infections; mechanical injury associated with trauma; hereditary diseases affecting pancreatitis; biliary disease; infiltrative diseases such as leukemias and lymphomas; or other physiologic and pathologic problems which affect the function of the organ.

Bioactive compositions comprising agonists, antagonists, receptors or inhibitors of PANEC-1 or PANEC-2 may be administered in a suitable therapeutic dose determined by any of several methodologies including clinical studies on mammalian species to determine maximal tolerable dose and on normal human subjects to determine safe dose. Additionally, the bioactive agent may be complexed with a variety of well established compounds or compositions which enhance stability or pharmacological properties such as half-life. It is contemplated that the therapeutic, bioactive composition may be delivered by intravenous infusion into the bloodstream or any other effective means which could be used for treating problems of the pancreas.

The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention.

EXAMPLES

I Isolation of mRNA and Construction of cDNA Libraries

The panec-1 and panec-2 cDNA sequences were identified among the sequences comprising the human pancreas library. The normal pancreas used for this library was obtained from the Keystone Skin Bank, International Institute for the Advancement of Medicine (Exton, PA). Normal pancreas tissue from a 56 year old Caucasian male (Lot HDS330) was flash frozen, ground in a mortar and pestle, and lysed immediately in buffer containing guanidinium isothiocyanate. Lysis was followed by several phenol chloroform extractions and ethanol precipitation. Poly A⁺ RNA was isolated using biotinylated oligo d(T) primer and streptavidin coupled to a paramagnetic particle (Promega Corp, Madison WI) and sent to Stratagene (11011 North Torrey Pines Road, La Jolla, CA 92037).

An alternate method of purifying phagemid has recently become available. It utilizes the Miniprep Kit (Catalog No. 77468, available from Advanced Genetic Technologies Corp., 19212 Orbit Drive, Gaithersburg, Maryland). This kit is in the 96-well format and provides enough reagents for 960 purifications. Each kit is provided with a recommended protocol, which has been employed except for the following changes. First, the 96 wells are each filled with only 1 ml of sterile terrific broth with carbenicillin at 25 mg/L and glycerol at 0.4%. After the wells are inoculated, the bacteria are cultured for 24 hours and lysed with 60 µl of lysis buffer. A centrifugation step (2900 rpm for 5 minutes) is performed before the contents of the block are added to the primary filter plate. The optional step of adding isopropanol to TRIS buffer is not routinely performed. After the last step in the protocol, samples are transferred to a Beckman 96-well block for storage.

Stratagene prepared the cDNA library using oligo d(T) priming. Synthetic adapter oligonucleotides were ligated onto the cDNA molecules enabling them to be inserted into the Uni-ZAPTM vector system (Stratagene). This allowed high efficiency unidirectional (sense orientation) lambda library construction and the convenience of a plasmid system with blue/white color selection to detect clones with cDNA insertions.

The quality of the cDNA library was screened using DNA probes, and then, the pBluescript[®] phagemid (Stratagene) was excised. This phagemid allows the use of a plasmid system for easy insert characterization, sequencing, site-directed mutagenesis, the creation of unidirectional deletions and expression of fusion polypeptides. Subsequently, the custom-constructed library phage particles were infected into *E. coli* host strain XL1-Blue[®] (Stratagene). The high transformation efficiency of this bacterial strain increases the probability that the cDNA library will

contain rare, under-represented clones. Alternative unidirectional vectors might include, but are not limited to, pcDNA1 (Invitrogen) and pSHlox-1 (Novagen).

5 II Isolation of cDNA Clones

The phagemid forms of individual cDNA clones were obtained by the in vivo excision process, in which XL1-BLUE was coinfectd with an f1 helper phage. Proteins derived from both lambda phage and f1 helper phage initiated new DNA synthesis from defined sequences on the lambda target DNA and create a smaller, single-stranded circular phagemid DNA molecule that includes all DNA sequences of the pBluescript plasmid and the cDNA insert. The phagemid DNA was released from the cells and purified, then used to re-infect fresh bacterial host cells (SOLR, Stratagene Inc), where the double-stranded phagemid DNA was produced. Because the phagemid carries the gene for β -lactamase, the newly transformed bacteria were selected on medium containing ampicillin.

Phagemid DNA was purified using the QIAWELL-8 Plasmid Purification System from QIAGEN[®] DNA Purification System (QIAGEN Inc, 9259 Eton Ave, Chatsworth, CA 91311). This technique provides a rapid and reliable high-throughput method for lysing the bacterial cells and isolating highly purified phagemid DNA. The DNA eluted from the purification resin was suitable for DNA sequencing and other analytical manipulations.

An alternate method of purifying phagemid has recently become available. It utilizes the Miniprep Kit (Catalog No. 77468, available from Advanced Genetic Technologies Corp., 19212 Orbit Drive, Gaithersburg, Maryland). This kit is in the 96-well format and provides enough reagents for 960 purifications. Each kit is provided with a recommended protocol, which has been employed except for the following changes. First, the 96 wells are each filled with only 1 ml of sterile terrific broth with carbenicillin at 25 mg/L and glycerol at 0.4%. After the wells are inoculated, the bacteria are cultured for 24 hours and lysed with 60 μ l of lysis buffer. A centrifugation step (2900 rpm for 5 minutes) is performed before the contents of the block are added to the primary filter plate. The optional step of adding isopropanol to TRIS buffer is not routinely performed. After the last step in the protocol, samples are transferred to a Beckman 96-well block for storage.

III Sequencing of cDNA Clones

The cDNA inserts from random isolates of the human pancreas library were sequenced in part. Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employed DNA polymerase Klenow

fragment, SEQUENASE® (US Biochemical Corp, Cleveland, OH) or Taq polymerase to extend DNA chains from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single- and double-stranded templates. The chain termination reaction products were electrophoresed on urea-acrylamide gels and detected either by autoradiography (for radionuclide-labeled precursors) or by fluorescence (for fluorescent-labeled precursors). Recent improvements in mechanized reaction preparation, sequencing and analysis using the fluorescent detection method have permitted expansion in the number of sequences that can be determined per day (using machines such as the Catalyst 800 and the Applied Biosystems 373 DNA sequencer).

IV Homology Searching of cDNA Clones and Deduced Proteins

Each sequence so obtained was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems Inc. and incorporated into the INHERIT™ 670 Sequence Analysis System. In this algorithm, Pattern Specification Language (developed by TRW Inc.) was used to determine regions of homology. The three parameters that determine how the sequence comparisons run were window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches. Smith-Waterman alignments were used to display the results of the homology search.

Peptide and protein sequence homologies were ascertained using the INHERIT 670 Sequence Analysis System in a way similar to that used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix homology plots were examined to distinguish regions of significant homology from chance matches.

The nucleotide and amino acid sequences for the entire coding region of the the pancreas expressed chemokines, PANEC-1 and PANEC-2, claimed in this invention are shown in Figure 1.

V Identification and Full Length Sequencing of the Genes

From all of the randomly picked and sequenced clones of the human pancreas library, the panec sequences were homologous to but clearly different from one another and from any known C-C chemokine molecule. The complete nucleotide sequences for panec-1 and panec-2 were translated, and the in-frame translations, as identified, are shown in Figs. 1 and 2,

respectively. When all three possible predicted translations of the sequence were searched against protein databases such as SwissProt and PIR, no exact matches were found to the possible translations of panec-1 or panec-2. Figure 3 shows the comparison of PANEC-1 and PANEC-2 amino acid sequences with other β chemokine molecules. The substantial regions of homology among these molecules which includes the definitive C-C motif are shaded. Hydrophobicity plots for PANEC-1 and PANEC-2 are shown as Figs. 4 and 5, respectively. The phylogenetic analysis (Figure 6) shows how closely panec-1 and panec-2 are related to one another and to other well characterized human C-C chemokines. The most related of these molecules cluster together at the right hand side of the figure.

VI Antisense analysis

Knowledge of the correct, complete cDNA sequences of novel expressed chemokine genes will enable their use in antisense technology in the investigation of gene function. Either oligonucleotides, genomic or cDNA fragments comprising the antisense strand of panec-1 or panec-2 can be used either in vitro or in vivo to inhibit expression of the specific protein. Such technology is now well known in the art, and probes can be designed at various locations along the nucleotide sequences. By treatment of cells or whole test animals with such antisense sequences, the gene of interest can be effectively turned off. Frequently, the function of the gene can be ascertained by observing behavior at the cellular, tissue or organismal level (e.g. lethality, loss of differentiated function, changes in morphology, etc.).

In addition to using sequences constructed to interrupt transcription of the open reading frame, modifications of gene expression can be obtained by designing antisense sequences to intron regions, promoter/enhancer elements, or even to trans-acting regulatory genes. Similarly, inhibition can be achieved using Hogeboom base-pairing methodology, also known as "triple helix" base pairing.

VII Expression of PANEC-1 and PANEC-2

Expression of panec-1 and panec-2 may be accomplished by subcloning the cDNAs into appropriate expression vectors and transfecting the vectors into an appropriate expression hosts. In this particular case, the cloning vector previously used for the generation of the tissue library also provide for direct expression of the included panec-1 and panec-2 sequences in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met and the subsequent 7 residues of β -galactosidase. Immediately following these eight residues is an engineered bacteriophage promoter useful for artificial priming and transcription and a number of unique restriction sites,

including Eco RI, for cloning.

Induction of the isolated, transfected bacterial strain with IPTG using standard methods will produce a fusion protein corresponding to the first seven residues of β -galactosidase, about 15 residues of "linker", and the peptide encoded within the cDNA. Since cDNA clone inserts are generated by an essentially random process, there is one chance in three that the included cDNA will lie in the correct frame for proper translation. If the cDNA is not in the proper reading frame, it can be obtained by deletion or insertion of the appropriate number of bases by well known methods including in vitro mutagenesis, digestion with exonuclease III or mung bean nuclease, or oligonucleotide linker inclusion.

Panec-1 or panec-2 cDNA can be shuttled into other vectors known to be useful for expression of protein in specific hosts. Oligonucleotide amplimers containing cloning sites as well as a segment of DNA sufficient to hybridize to stretches at both ends of the target cDNA (25 bases) can be synthesized chemically by standard methods. These primers can then used to amplify the desired gene segments by PCR. The resulting new gene segments can be digested with appropriate restriction enzymes under standard conditions and isolated by gel electrophoresis. Alternately, similar gene segments can be produced by digestion of the cDNA with appropriate restriction enzymes and filling in the missing gene segments with chemically synthesized oligonucleotides. Segments of the coding sequence from more than one gene can be ligated together and cloned in appropriate vectors to optimize expression of recombinant sequence.

Suitable expression hosts for such chimeric molecules include but are not limited to mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells, insect cells such as Sf9 cells, yeast cells such as *Saccharomyces cerevisiae*, and bacteria such as *E. coli*. For each of these cell systems, a useful expression vector may also include an origin of replication to allow propagation in bacteria and a selectable marker such as the β -lactamase antibiotic resistance gene to allow selection in bacteria. In addition, the vectors may include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected eukaryotic host cells. Vectors for use in eukaryotic expression hosts may require RNA processing elements such as 3' polyadenylation sequences if such are not part of the cDNA of interest.

Additionally, the vector may contain promoters or enhancers which increase gene expression. Such promoters are host specific and include MMTV, SV40, or metallothionine promoters for CHO cells; trp, lac, tac or T7 promoters for bacterial hosts, or alpha factor, alcohol oxidase or PGH promoters for yeast. Transcription enhancers, such as the rous sarcoma

virus (RSV) enhancer, may be used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through standard culture methods, large quantities of recombinantly produced PANEC-1 and PANEC-2 can be recovered from the conditioned medium and analyzed using chromatographic methods known in the art.

VIII Isolation of Recombinant PANEC-1 and PANEC-2

PANEC may be expressed as a chimeric protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle WA). The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen, San Diego CA) between the purification domain and the panec sequence may be useful to facilitate expression of PANEC.

IX Production of PANEC-1 and PANEC-2 Specific Antibodies

Two approaches are utilized to raise antibodies to PANEC-1 and PANEC-2, and each approach is useful for generating either polyclonal or monoclonal antibodies. In one approach, denatured protein from the reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein can be used to immunize mice or rabbits using standard protocols; about 100 micrograms are adequate for immunization of a mouse, while up to 1 mg might be used to immunize a rabbit. For identifying mouse hybridomas, the denatured protein can be radioiodinated and used to screen potential murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg would be sufficient for labeling and screening of several thousand clones.

In the second approach, the amino acid sequence of PANEC-1 or PANEC-2, as deduced from translation of the cDNA, is analyzed to determine regions of high immunogenicity. Oligopeptides comprising appropriate hydrophilic regions, as shown in Figures 4 and 5, are synthesized and used in suitable immunization protocols to raise antibodies. Analysis to select appropriate epitopes is described by Ausubel FM et al (1989, Current Protocols in Molecular Biology, John Wiley & Sons, NYC). The optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the protein is in its natural conformation.

Typically, selected peptides, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using

fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M -maleimidobenzoyl-N- hydroxysuccinimide ester (MBS; cf. Ausubel FM et al, supra). If necessary, a cysteine may be introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% BSA, reacting with antisera, washing and reacting with labeled (radioactive or fluorescent), affinity purified, specific goat anti-rabbit IgG.

Hybridomas may also be prepared and screened using standard techniques. Hybridomas of interest are detected by screening with labeled PANEC-1 or PANEC-2 to identify those fusions producing the monoclonal antibody with the desired specificity. In a typical protocol, wells of plates (FAST; Becton-Dickinson, Palo Alto, CA) are coated with affinity purified, specific rabbit-anti-mouse (or suitable anti-species Ig) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA, washed and exposed to supernatants from hybridomas. After incubation the wells are exposed to labeled PANEC-1 or PANEC-2, 1 mg/ml. Clones producing antibodies will bind a quantity of labeled PANEC-1 or PANEC-2 which is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning at limiting dilution (1 cell/3 wells). Cloned hybridomas are injected into pristine mice to produce ascites, and monoclonal antibody is purified from mouse ascitic fluid by affinity chromatography on Protein A. Monoclonal antibodies with affinities of at least 10^8 M⁻¹, preferably 10^9 to 10^{10} or stronger, will typically be made by standard procedures as described in Harlow and Lane (1988) Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory NY; and in Goding (1986) Monoclonal Antibodies: Principles and Practice, Academic Press, NYC, both incorporated herein by reference.

X Diagnostic Test Using PANEC-1 and PANEC-2 Specific Antibodies

Particular PANEC-1 or PANEC-2 antibodies are useful for the diagnosis of prepathologic conditions, and chronic or acute diseases which are characterized by differences in the amount or distribution of PANEC-1 or PANEC-2, respectively. To date, PANEC-1 and PANEC-2 has only been found in the human pancreas library and is thus specific for abnormalities or pathologies which affect the pancreas.

Diagnostic tests for PANEC include methods utilizing the antibody and a label to detect PANEC in human body fluids, tissues or extracts of such tissues. The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a substance which provides for a detectable signal. A

wide variety of labels and conjugation techniques are known and have been reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, magnetic particles and the like. Patents teaching the use of such labels include US Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in US Patent No. 4,816,567, incorporated herein by reference.

A variety of protocols for measuring soluble or membrane-bound PANEC-1 or PANEC-2, using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PANEC-1 or PANEC-2 is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, DE et al (1983, J Exp Med 158:1211).

XI Purification of Native PANEC-1 and PANEC-2 Using Specific Antibodies

Native or recombinant PANEC-1 or PANEC-2 can be purified by immunoaffinity chromatography using antibodies specific for either PANEC-1 or PANEC-2, respectively. In general, an immunoaffinity column is constructed by covalently coupling the anti- PANEC-1 or PANEC-2 antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, NJ). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such immunoaffinity columns were utilized in the purification of PANEC-1 and PANEC-2 by preparing a fraction from cells containing PANEC-1 or PANEC-2 in a soluble form. This preparation was derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble PANEC-1 or PANEC-2 containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.

A soluble PANEC-1 or PANEC-2 -containing preparation was passed over

the immunoaffinity column, and the column was washed under conditions that allow the preferential absorbance of chemokines (eg, high ionic strength buffers in the presence of detergent). Then, the column was eluted under conditions that disrupt antibody/chemokine binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and PANEC-1 or PANEC-2 was collected.

XII PANEC-1 and PANEC-2 Induced Chemotaxis or Cell Activation

The chemotactic activities of PANEC-1 and PANEC-2 were measured in 48-well microchemotaxis chambers (Falk WR et al (1980) J Immunol Methods 33:239). In each well, two compartments are separated by a filter that allows the passage of cells in response to a chemical gradient. Cell culture medium such as RPMI 1640 (Sigma, St. Louis MO) containing the expressed chemokine is placed on one side of a filter, usually polycarbonate, and cells suspended in the same media are placed on the opposite side of the filter. Sufficient incubation time is allowed for the cells to traverse the filter in response to the concentration gradient across the filter. Filters are recovered from each well, and cells adhering to the side of the filter facing the chemokine are typed and quantified.

The specificity of the chemoattraction is determined by performing the chemotaxis assay on specific populations of cells. First, blood cells obtained from venipuncture are fractionated by density gradient centrifugation and the chemotactic activity of PANEC-1 or PANEC-2 is tested on enriched populations of neutrophils, peripheral blood mononuclear cells, monocytes and lymphocytes. Optionally, such enriched cell populations are further fractionated using CD8+ and CD4+ specific antibodies for negative selection of CD4+ and CD8+ enriched T-cell populations, respectively.

Another assay elucidates the chemotactic effect of PANEC-1 or PANEC-2 on activated T-cells. There, unfractionated T-cells or fractionated T-cell subsets are cultured for 6 to 8 hours in tissue culture vessels coated with CD-3 antibody. After this CD-3 activation, the chemotactic activity of PANEC-1 or PANEC-2 is tested as described above. Many other methods for obtaining enriched cell populations are known in the art.

Some chemokines also produce a non-chemotactic cell activation of neutrophils and monocytes. This is tested via standard measures of neutrophil activation such as actin polymerization, increase in respiratory burst activity, degranulation of the azurophilic granule and mobilization of Ca^{++} as part of the signal transduction pathway. The assay for mobilization of Ca^{++} involves preloading neutrophils with a fluorescent probe whose emission characteristics have been altered by Ca^{++} binding. When the cells are exposed to an activating stimulus, Ca^{++} flux is determined by observation

of the cells in a fluorometer. The measurement of Ca^{++} mobilization has been described in Grynkiewicz G et al. (1985) J Biol Chem 260:3440, and McColl S et al. (1993) J Immunol 150:4550-4555, incorporated herein by reference.

5 Degranulation and respiratory burst responses are also measured in monocytes (Zachariae COC et al. (1990) J Exp Med 171: 2177-82). Further measures of monocyte activation are regulation of adhesion molecule expression and cytokine production (Jiang Y et al. (1992) J Immunol 148: 2423-8). Expression of adhesion molecules also varies with lymphocyte activation (Taub D et al. (1993) Science 260: 355-358).

10 XIII Drug Screening

This invention is particularly useful for screening compounds by using PANEC-1 or PANEC-2 polypeptide or binding fragments thereof in any of a variety of drug screening techniques. The chemokine polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between PANEC-1 or PANEC-2 and the agent being tested. Alternatively, one can examine the diminution in complex formation between PANEC-1 or PANEC-2 and its target cell, monocyte, etc. caused by the agent being tested.

25 Thus, the present invention provides methods of screening for drugs or any other agents which can affect inflammation and disease. These methods comprise contacting such an agent with a PANEC-1 or PANEC-2 polypeptide or fragment thereof and assaying (i) for the presence of a complex between the agent and the PANEC-1 or PANEC-2 polypeptide or fragment, or (ii) for the presence of a complex between the PANEC-1 or PANEC-2 polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the chemokine polypeptide or fragment is typically labeled. After suitable incubation, free PANEC-1 or PANEC-2 polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PANEC-1 or PANEC-2 or to interfere with the PANEC-1 or PANEC-2 and agent complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the PANEC-1 or PANEC-2 polypeptides and is described in detail in European Patent Application 84/03564, published on September 13, 1984, incorporated herein

by reference. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with PANEC-1 or PANEC-2 polypeptide and washed. Bound PANEC-1 or PANEC-2 polypeptide is then detected by methods well known in the art. Purified PANEC-1 or PANEC-2 can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding PANEC-1 or PANEC-2 specifically compete with a test compound for binding to chemokine polypeptides or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PANEC-1 or PANEC-2.

XIV Rational Drug Design

The goal of rational drug design is to produce structural analogs of biologically active polypeptides of interest or of small molecules with which they interact, e.g., agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or stable forms of the polypeptide or which enhance or interfere with the function of a polypeptide in vivo (cf Hodgson J (1991) Bio/Technology 9:19-21, incorporated herein by reference).

In one approach, the three-dimensional structure of a protein of interest, or of a protein-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide may be gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous chemokine-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton S and Wells JA (1992 Biochemistry 31:7796- 7801) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda SB et al (1993 J Biochem 113:742-746), incorporated herein by reference.

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies

(anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then act as the pharmacore.

By virtue of the present invention, sufficient amount of polypeptide may be made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the PANEC amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

XV Identification of PANEC-1 and PANEC-2 Receptors

Purified PANEC-1 and PANEC-2 are useful for characterization and purification of specific cell surface receptors and other binding molecules. Cells which respond to PANEC-1 and PANEC-2 by chemotaxis or other specific responses are likely to express a receptor for PANEC-1 and PANEC-2, respectively. Radioactive labels may be incorporated into PANEC-1 and PANEC-2 by various methods known in the art. A preferred embodiment is the labeling of primary amino groups in PANEC-1 and PANEC-2 with ^{125}I Bolton-Hunter reagent (Bolton, AE and Hunter, WM (1973) Biochem J 133: 529), which has been used to label other chemokines without concomitant loss of biological activity (Hebert CA et al (1991) J Biol Chem 266: 18989; McColl S et al (1993) J Immunol 150:4550-4555). Receptor-bearing cells are incubated with the labeled chemokine molecule. The cells are then washed to removed unbound chemokine, and receptor-bound labeled molecule is quantified. The data obtained using different concentrations of PANEC-1 or PANEC-2 are used to calculate values for the number and affinity of receptors.

Labeled PANEC-1 or PANEC-2 is also useful as a reagent for purification of its specific receptor. In one embodiment of affinity purification, the chemokine is covalently coupled to a chromatography column. Receptor-bearing cells are extracted, and the extract is passed over the column. The receptor binds to the column by virtue of its biological affinity for either PANEC-1 or PANEC-2. The receptor is recovered from the column and subjected to N-terminal protein sequencing. This amino acid sequence is then used to design degenerate oligonucleotide probes for cloning the receptor gene.

In an alternate method, mRNA is obtained from receptor-bearing cells and made into a cDNA library. The library is transfected into a population of cells, and those cells expressing the receptor are selected using fluorescently labeled PANEC-1 or PANEC-2. The PANEC-1 or PANEC-2 specific receptor is identified by recovering and sequencing recombinant DNA from highly labeled cells.

In another alternate method, antibodies are raised against the surface of receptor-bearing cells, specifically monoclonal antibodies. The monoclonal antibodies are screened to identify those which inhibit the binding of labeled PANEC-1 or PANEC-2. These monoclonal antibodies are then used in affinity purification or expression cloning of the receptor.

Soluble receptors or other soluble binding molecules are identified in a similar manner. Labeled PANEC-1 or PANEC-2 is incubated with extracts or other appropriate materials derived from the pancreas. After incubation, PANEC-1 or PANEC-2 complexes (which are larger than the size of purified the purified chemokine molecule) are identified by a sizing technique such as size exclusion chromatography or density gradient centrifugation and are purified by methods known in the art. The soluble receptors or binding protein(s) are subjected to N-terminal sequencing to obtain information sufficient for database identification, if the soluble protein is known, or for cloning, if the soluble protein is unknown.

XVI Use and Administration of PANEC-1 and PANEC-2

Antibodies, inhibitors, receptors or antagonists of PANEC-1 and PANEC-2 (or other treatments for excessive chemokine production, hereinafter abbreviated TEC), can provide different effects when administered therapeutically. TECs will be formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium preferably at a pH of about 5 to 8, more preferably 6 to 8, although the pH may vary according to the characteristics of the antibody, inhibitor, receptor or antagonist being formulated and the condition to be treated. Characteristics of TEC include solubility of the molecule, half-life and antigenicity/immuno-genicity; these and other characteristics may aid in defining an effective carrier. Native human proteins are preferred as TECs, but organic or synthetic molecules resulting from drug screens may be equally effective in particular situations.

TECs may be delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol, transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills, particularly formulated to resist stomach acid and enzymes. The particular formulation, exact dosage, and route of administration will be determined by the attending physician and will vary according to each specific situation.

Such determinations are made by considering multiple variables such as the condition to be treated, the TEC to be administered, and the pharmacokinetic profile of the particular TEC. Additional factors which may be taken into account include disease state (e.g. severity) of the patient, age, weight, gender, diet, time of administration, drug combination,

reaction sensitivities, and tolerance/response to therapy. Long acting TEC formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular TEC.

5 Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see US Patent No. 4,657,760; 5,206,344; or 5,225,212. It is anticipated that different formulations will be effective for different TECs and that administration targeting the pancreas may necessitate delivery in a
10 manner different from that to another organ or tissue.

 It is contemplated that conditions or diseases of the pancreas which activate monocytes, macrophages, basophils, eosinophils or other leukocytes may precipitate damage that is treatable with TECs. These conditions or
15 diseases may be specifically diagnosed by the tests discussed above, and such testing should be performed in suspected cases of viral or bacterial infections; mechanical injury associated with trauma; hereditary diseases affecting pancreatitis; biliary disease; infiltrative diseases such as leukemias and lymphomas; or other physiologic and pathologic problems which
20 affect the function of the organ.

 All publications and patents mentioned in the above specification are herein incorporated by reference. The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above described modes for
25 carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Incyte Pharmaceuticals, Inc.
- (ii) TITLE OF INVENTION: NEW CHEMOKINES EXPRESSED IN PANCREAS
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: INCYTE PHARMACEUTICALS, INC.
 - (B) STREET: 3174 PORTER DRIVE
 - (C) CITY: PALO ALTO
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) PCT APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: 16-FEB-1996
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION SERIAL NO: US 08/390,740
 - (B) FILING DATE: 17-FEB-1995
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Luther, Barbara J.
 - (B) REGISTRATION NUMBER: 33954
 - (C) REFERENCE/DOCKET NUMBER: PF-0027 PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 415-855-0555
 - (B) TELEFAX: 415-852-0195

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 289 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: 223187

(B) CLONE: HUMAN PANCREAS

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGAAGGTCT CCGCAGCACT TCTGTGGCTG CTGCTCATAG CAGCTGCCTT CAGCCCCCAG	60
GGGCTCACTG GGCCAGCTTC TGTCCCAACC ACCTGCTGCT TTAACCTGGC CAATAGGAAG	120
ATACCCCTTC AGCGACTAGA GAGCTACAGG AGAATCACCA GTGGCAAATG TCCCCAGAAA	180
GCTGTGATCT TCAAGACCAA ACTGGCCAAG GATATCTGTG CCGACCCCAA GAAGAAGTGG	240
GTGCAGGATT CCATGAAGTA TCTGGACCAA AAATCTCCAA CTCCAAAGC	289

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 97 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: HUMAN PANCREAS

(B) CLONE: 223187

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Lys	Val	Ser	Ala	Ala	Leu	Leu	Trp	Leu	Leu	Ile	Ala	Ala	Ala
1				5				10				15		
Phe	Ser	Pro	Gln	Gly	Leu	Thr	Gly	Pro	Ala	Ser	Val	Pro	Thr	Cys
			20				25					30		
Cys	Phe	Asn	Leu	Ala	Asn	Arg	Lys	Ile	Pro	Leu	Gln	Arg	Leu	Glu
		35					40					45		Ser
Tyr	Arg	Arg	Ile	Thr	Ser	Gly	Lys	Cys	Pro	Gln	Lys	Ala	Val	Ile
			50			55					60			Phe

Lys Thr Lys Leu Ala Lys Asp Ile Cys Ala Asp Pro Lys Lys Lys Trp
 65 70 75 80

Val Gln Asp Ser Met Lys Tyr Leu Asp Gln Lys Ser Pro Thr Pro Lys
 85 90 95

Pro

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 402 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: HUMAN PANCREAS
- (B) CLONE: 226152

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGGCTCAGT CACTGGCTCT GAGCCTCCTT ATCCTGGTTC TGGCCTTTGG CATCCCCAGG	60
ACCCAAGGCA GTGATGGAGG GGCTCAGGAC TGTTGCCTCA AGTACAGCCA AAGGAAGATT	120
CCCGCCAAGG TTGTCCGCAG CTACCGGAAG CAGGAACCAA GCTTAGGCTG CTCCATCCCA	180
GCTATCCTGT TCTTGCCCCG CAAGCGCTCT CAGGCAGAGC TATGTGCAGA CCCAAAGGAG	240
CTCTGGGTGC AGCAGCTGAT GCAGCATCTG GACAAGACAC CATCCCCACA GAAACCAGCC	300
CAGGGCTGCA GGAAGGACAG GGGGGCCTCC AAGACTGGCA AGAAAGGAAA GGGCTCCAAA	360
GGCTGCAAGA GGACTGAGCG GTCACAGACC CCTAAAGGGC CA	402

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 134 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: HUMAN PANCREAS
 (B) CLONE: 226152

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Ala Gln Ser Leu Ala Leu Ser Leu Leu Ile Leu Val Leu Ala Phe
1              5              10              15

Gly Ile Pro Arg Thr Gln Gly Ser Asp Gly Gly Ala Gln Asp Cys Cys
              20              25              30

Leu Lys Tyr Ser Gln Arg Lys Ile Pro Ala Lys Val Val Arg Ser Tyr
35              40              45

Arg Lys Gln Glu Pro Ser Leu Gly Cys Ser Ile Pro Ala Ile Leu Phe
50              55              60

Leu Pro Arg Lys Arg Ser Gln Ala Glu Leu Cys Ala Asp Pro Lys Glu
65              70              75              80

Leu Trp Val Gln Gln Leu Met Gln His Leu Asp Lys Thr Pro Ser Pro
              85              90              95

Gln Lys Pro Ala Gln Gly Cys Arg Lys Asp Arg Gly Ala Ser Lys Thr
              100              105              110

Gly Lys Lys Gly Lys Gly Ser Lys Gly Cys Lys Arg Thr Glu Arg Ser
              115              120              125

Gln Thr Pro Lys Gly Pro
              130

```


CLAIMS

5

1. A recombinant DNA molecule comprising pancreas expressed chemokine (panec-1) gene, whose nucleotide sequence is shown in SEQ ID NO 1.

2. A diagnostic test for activated or inflammatory conditions of the pancreas comprising the steps of

10

a) providing a biological sample; and

b) combining the biological sample with the DNA molecule of claim 1 or a fragment thereof.

3. The diagnostic test of claim 2 wherein the activated condition comprises pancreatitis.

15

4. The antisense DNA of the DNA molecule of claim 1.

5. An expression vector comprising the DNA molecule of claim 1.

6. A host cell transformed with the expression vector of claim 5.

7. A method for producing the pancreas expressed chemokine polypeptide (PANEC-1), said method comprising the steps of

20

a) culturing the host cells of claim 6 under conditions suitable for the expression of PANEC-1; and

b) recovering PANEC-1 from the cell culture.

8. A purified PANEC-1 polypeptide whose amino acid sequence is shown in SEQ ID NO 2.

25

9. An antibody specific for the polypeptide of claim 8.

10. A diagnostic test for activated or inflamed conditions of the pancreas comprising the steps of

a) providing a biological sample; and

b) combining the biological sample with the antibody of claim 9.

30

11. A pharmaceutical composition comprising the antibody of claim 9 and a pharmaceutically acceptable excipient.

12. A method of treating the activated or inflamed condition of the pancreas comprising administering to an individual suffering therefrom the pharmaceutical composition of claim 11 in an effective dosage.

35

13. A recombinant DNA molecule comprising pancreas expressed chemokine (panec-2) gene, whose nucleotide sequence is shown in SEQ ID NO 3.

14. A diagnostic test for activated or inflammatory conditions of the pancreas comprising the steps of

a) providing a biological sample; and

40

b) combining the biological sample with the DNA molecule of claim 13 or a fragment thereof.

15. The diagnostic test of claim 14 wherein the activated condition comprises pancreatitis.

16. The antisense DNA of the DNA molecule of claim 13.

17. An expression vector comprising the DNA molecule of claim 13.

5 18. A host cell transformed with the expression vector of claim 17.

19. A method for producing the pancreas expressed chemokine polypeptide (PANEK-2), said method comprising the steps of
a) culturing the host cells of claim 18 under conditions suitable for the expression of PANEK-2; and

10 b) recovering PANEK-2 from the cell culture.

20. A purified PANEK-2 polypeptide whose amino acid sequence is shown in SEQ ID NO 4.

21. An antibody specific for the polypeptide of claim 20.

15 22. A diagnostic test for activated or inflamed conditions of the pancreas comprising the steps of

a) providing a biological sample; and

b) combining the biological sample with the antibody of claim 21.

23. A pharmaceutical composition comprising the antibody of claim 21 and a pharmaceutically acceptable excipient.

20 24. A method of treating an activated or inflamed condition of the pancreas comprising administering to an individual suffering therefrom the pharmaceutical composition of claim 23 in an effective dosage.

25

```

5' ATG AAG GTC TCC GCA GCA CTT CTG TGG CTG CTG CTC ATA GCA GCT GCC TTC AGC
   M  K  V  S  A  A  L  L  W  L  L  L  I  A  A  A  F  S

      58      67      76      85      94      103
CCC CAG GGG CTC ACT GGG CCA GCT TCT GTC CCA ACC ACC TGC TGC TTT AAC CTG
P  Q  G  L  T  G  P  A  S  V  P  T  T  C  C  F  N  L

      112      121      130      139      148      157
GCC AAT AGG AAG ATA CCC CTT CAG CGA CTA GAG AGC TAC AGG AGA ATC ACC AGT
A  N  R  K  I  P  L  Q  R  L  E  S  Y  R  R  I  T  S

      166      175      184      193      202      211
GGC AAA TGT CCC CAG AAA GCT GTG ATC TTC AAG ACC AAA CTG GCC AAG GAT ATC
G  K  C  P  Q  K  A  V  I  F  K  T  K  L  A  K  D  I

      220      229      238      247      256      265
TGT GCC GAC CCC AAG AAG AAG TGG GTG CAG GAT TCC ATG AAG TAT CTG GAC CAA
C  A  D  P  K  K  K  W  V  Q  D  S  M  K  Y  L  D  Q

      274      283      292      301      310      319
AAA TCT CCA ACT CCA AAG CCA 3'
K  S  P  T  P  K  P

```

FIGURE 1

2/6

```

      39      48      57      66      75      84
5' ATG GCT CAG TCA CTG GCT CTG AGC CTC CTT ATC CTG GTT CTG GCC TTT GGC ATC
   M  A  Q  S  L  A  L  S  L  L  I  L  V  L  A  F  G  I

      93      102      111      120      129      138
CCC AGG ACC CAA GGC AGT GAT GGA GGG GCT CAG GAC TGT TGC CTC AAG TAC AGC
P  R  T  Q  G  S  D  G  G  A  Q  D  C  C  L  K  Y  S

      147      156      165      174      183      192
CAA AGG AAG ATT CCC GCC AAG GTT GTC CGC AGC TAC CGG AAG CAG GAA CCA AGC
Q  R  K  I  P  A  K  V  V  R  S  Y  R  K  Q  E  P  S

      201      210      219      228      237      246
TTA GGC TGC TCC ATC CCA GCT ATC CTG TTC TTG CCC CGC AAG CGC TCT CAG GCA
L  G  C  S  I  P  A  I  L  F  L  P  R  K  R  S  Q  A

      255      264      273      282      291      300
GAG CTA TGT GCA GAC CCA AAG GAG CTC TGG GTG CAG CAG CTG ATG CAG CAT CTG
E  L  C  A  D  P  K  E  L  W  V  Q  Q  L  M  Q  H  L

      309      318      327      336      345      354
GAC AAG ACA CCA TCC CCA CAG AAA CCA GCC CAG GGC TGC AGG AAG GAC AGG GGG
D  K  T  P  S  P  Q  K  P  A  Q  G  C  R  K  D  R  G

      363      372      381      390      399      408
GCC TCC AAG ACT GGC AAG AAA GGA AAG GGC TCC AAA GGC TGC AAG AGG ACT GAG
A  S  K  T  G  K  K  G  K  G  S  K  G  C  K  R  T  E

      417      426
CGG TCA CAG ACC CCT AAA GGG CCA 3'
R  S  Q  T  P  K  G  P

```

FIGURE 2

M - - - - - K V S A A L L A L L I A A A F C P Q																														Majority		
1	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MIP-1a		
1	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MIP-1b		
1	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	RANTES		
1	M	A	Q	S	L	A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	226152		
1	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MCP-1		
1	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MCP-2		
1	M	W	K	P	M	P	S	P	S	N	M	K	A	S	A	A	L	L	C	L	L	L	T	A	A	A	F	S	P	Q	MCP-3	
1	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	223187		
G L A Q P D G V D T P T T C C F N Y I N R K I P R Q R L E S																														Majority		
21	-	F	S	A	S	L	A	A	D	T	P	T	A	C	C	F	S	Y	T	S	R	Q	I	P	Q	N	F	I	A	D	MIP-1a	
21	A	L	S	A	P	M	G	S	D	P	P	T	A	C	C	F	S	Y	T	A	R	K	L	P	R	N	F	V	D	-	MIP-1b	
21	A	S	A	S	P	Y	S	S	D	T	-	T	P	C	C	F	A	Y	I	A	R	P	L	P	R	A	H	I	K	E	-	RANTES
20	R	T	Q	G	S	D	G	G	A	Q	D	-	-	C	C	L	K	Y	S	Q	R	K	I	P	A	K	V	V	R	S	-	226152
21	G	L	A	Q	P	D	A	I	N	A	P	V	T	C	C	Y	N	F	T	N	R	K	I	S	V	Q	R	L	A	S	-	MCP-1
1	-	-	A	Q	P	D	S	V	S	I	P	I	T	C	C	F	N	V	I	N	R	K	I	P	I	Q	R	L	E	S	-	MCP-2
31	G	L	A	O	P	V	G	I	N	T	S	T	T	C	C	Y	R	F	I	N	K	K	I	P	K	Q	R	L	E	S	-	MCP-3
21	G	L	T	G	P	A	S	V	-	-	P	T	T	C	C	F	N	L	A	N	R	K	I	P	L	O	R	L	E	S	-	223187
Y R R I T S S K - C S K P A V I F K T K R A K Q - - V C A D																														Majority		
50	Y	F	-	E	T	S	S	Q	-	C	S	K	P	G	V	I	F	L	T	K	R	S	R	Q	-	-	V	C	A	D	MIP-1a	
51	Y	Y	-	E	T	S	S	L	-	C	S	Q	P	A	V	V	F	Q	T	K	R	S	K	Q	-	-	V	C	A	D	-	MIP-1b
50	Y	F	-	Y	T	S	G	K	-	C	S	N	P	A	V	V	F	V	T	R	K	N	R	Q	-	-	V	C	A	N	-	RANTES
48	Y	R	K	Q	E	P	S	L	G	C	S	I	P	A	I	L	F	L	P	R	K	R	S	O	A	E	L	C	A	D	-	226152
51	Y	R	R	I	T	S	S	K	-	C	P	K	E	A	V	I	F	K	T	I	V	A	K	E	-	-	I	C	A	D	-	MCP-1
29	Y	T	R	I	T	N	I	Q	-	C	P	K	E	A	V	I	F	K	T	K	R	G	K	E	-	-	V	C	A	D	-	MCP-2
61	Y	R	R	T	T	S	S	H	-	C	P	R	E	A	V	I	F	K	T	K	L	D	K	E	-	-	I	C	A	D	-	MCP-3
49	Y	R	R	I	T	S	G	K	-	C	P	Q	K	A	V	I	F	K	T	K	L	A	K	D	-	-	I	C	A	D	-	223187
P K E K W V Q D S M K H L D K - - - - -																														Majority		
76	P	S	E	E	W	V	Q	K	Y	V	S	D	L	E	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MIP-1a	
77	P	S	E	S	W	V	Q	E	Y	V	D	L	E	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MIP-1b	
76	P	E	K	K	W	V	R	E	Y	I	N	S	L	E	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	RANTES	
78	P	K	E	L	W	V	Q	Q	L	M	Q	H	L	D	K	T	P	S	P	Q	K	P	A	Q	G	C	R	K	D	R	-	226152
78	P	K	Q	K	W	V	O	D	S	M	D	H	L	D	K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MCP-1	
56	P	K	E	R	W	V	R	D	S	M	K	H	L	D	Q	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MCP-2	
88	P	T	Q	K	W	V	Q	D	E	M	K	H	L	D	K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MCP-3	
76	P	K	K	K	W	V	O	D	S	M	K	Y	L	D	Q	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	223187	
- - - - - Q T P K - P																														Majority		
90	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MIP-1a	
91	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MIP-1b	
90	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	RANTES	
108	G	A	S	K	T	G	K	K	G	K	G	S	K	G	C	K	R	T	E	R	S	Q	T	P	K	G	P	-	-	-	226152	
93	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MCP-1	
71	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MCP-2	
103	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	MCP-3	
91	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	223187	

FIGURE 3




FIGURE 4

5/6




FIGURE 5

6/6




FIGURE 6

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/02225

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/19 C07K14/52 C12N15/11 A61K38/19 G01N33/68 C12Q1/68 C12N1/21 C07K16/24 A61K39/395		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF EXPERIMENTAL MEDICINE, vol. 179, no. 3, 1 March 1994, pages 881-887, XP002003776 P.J. JOSE ET AL: "Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation" see the whole document <div style="text-align: center;">--- -/--</div>	1,8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">30 May 1996</div>		Date of mailing of the international search report <div style="text-align: center;">27.06.96</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer <div style="text-align: center;">Le Cornec, N</div>

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/02225

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 205, no. 1, 30 November 1994, ORLANDO, FL US, pages 788-794, XP002003777 P.J. JOSE ET AL: "Eotaxin: Cloning of an eosinophil chemoattractant cytokine and increased mRNA expression in allergen-challenged guinea-pig lungs " see the whole document ----	1,5-8
P,A	WO,A,95 07985 (NATIONAL HEART & LUNG INSTITUTE) 23 March 1995 see the whole document ----	1,5-8
P,X	THE JOURNAL OF CLINICAL INVESTIGATION, vol. 97, no. 3, 1 February 1996, pages 604-612, XP000571506 P.D. PONATH ET AL: "Cloning of the human eosinophil chemoattractant , Eotaxin" see the whole document -----	1,5-9

Information on patent family members

PCT/US 96/02225

03-04-95

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 02225

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
REMARK: ALTHOUGH CLAIMS 12 AND 24 ARE DIRECTED TO A METHOD OF TREATMENT OF THE HUMAN/ANIMAL BODY (RULE 39.1(IV)PCT) THE SEARCH HAS BEEN CARRIED OUT AND BASED ON THE ALLEGED EFFECTS OF THE COMPOUND/COMPOSITION.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ID AAT33528
 CS e6935b06e129832f1a8ff52023b58ade
 IDH AAT33528 standard; cDNA; 402 BP.
 MO DNA
 DV DNA
 DT1 02-MAY-1997 (first entry)
 DT 02-MAY-1997
 AK PATENT WO9625497-A1
 AK PRIMARY AC AAT33528
 EAK
 DR P-PSDB AAW00668
 DR WPI 1996-393398/39
 EDR
 DE Pancreas expressed chemokine-2 gene.
 KW PANEC-1
 KW PANEC-2
 KW Pancreas-derived chemokine
 KW cancer
 KW diagnosis
 KW disease
 KW inflammation
 KW ss
 EKW
 OS Homo sapiens.
 SC 4a22b9fcfbf65eca55a08e9eb4312eae
 SP HOMO SAPIENS
 ESP
 INST (INCY-) INCYTE PHARM INC
 CC The sequences given in AAT33527-28 encode pancreas-derived chemokines,
 CC PANEC-1 and PANEC-2. These chemokines are highly expressed and
 CC specifically expressed in the pancreas and may therefore be used in
 CC diagnostic assays based on chemokine production in cases of
 CC inflammation or disease affecting the pancreas. These assays allow
 CC the early and accurate diagnosis of pancreatic disorders, and can
 CC differentiate between invasive diseases and genetic syndromes.
 ECC
 RN 1 d3b9129d1f7f1725d1b0465d5d90c24a
 RC PD: 22-AUG-1996. PF: 16-FEB-1996; 96WO-US02225. PR: 17-FEB-1995; 95US-
 0390740.
 RT Nucleotide and protein sequences for human PANEC-1 and PANEC-2 - useful
 in diagnosis and therapy of pancreatic diseases
 RL Patent: WO9625497-A1. Claim 13; Page 29; 43pp; English.
 RA Bandman O. BANDMAN O
 RA Coleman R. COLEMAN R
 RA Wilde C.G. WILDE CG
 ERN
 SQH Sequence 402 BP; 101 A; 120 C; 116 G; 65 T; 0 other;
 SL 402 92587c58af50d46898d32c89e2dcd520
 SQ atggctcagtcactggctctgagcctccttattcctgggttctggcctttggcatccccagg
 SQ acccaaggcagtgatggaggggctcaggactgttgctcaagtaacagccaaaggaagatt
 SQ cccgccaagggttgctccgcagctaccggaagcaggaaccaagcttaggctgctccatccca
 SQ gctatcctgttcttggccccgaagcgctctcaggcagagctatgtgcagacccaaaggag
 SQ ctctgggtgcagcagctgatgcagcatctggacaagacaccatccccacagaaaccagcc
 SQ cagggtgcaggaaggacaggggggctccaagactggcaagaaaggaaagggtcctccaa
 SQ ggctgcaagaggactgagcgggtcacagaccctaaagggcca
 ESQ

NCBI-BLASTN 2.0.10 [Aug-26-1999]

Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

Query= SEQ ID NO:3_Panec-2_PF-0027US
(402 letters)

Database: Geneseq.NA.2002AUG30
2,085,897 sequences; 1,057,821,503 total letters

Searching.....done

Sequences producing significant alignments:	Score (bits)	E Value
GSEQ:ABK81381 cDNA encoding small inducible cytokine subfamil	797	0.0
GSEQ:ABL95690 Human angiogenesis related cDNA PRO1600 SEQ ID	797	0.0
GSEQ:ABL88201 Human PRO1600 cDNA sequence SEQ ID NO:259.	797	0.0
GSEQ:ABL64073 Breast cancer related gene sequence SEQ ID NO:2	797	0.0
GSEQ:ABL63678 Breast cancer related gene sequence SEQ ID NO:2	797	0.0
GSEQ:AAH45099 Human SLC-interleukin-2 fusion protein coding s	797	0.0
GSEQ:AAH45084 Human SLC-interleukin-2 fusion protein coding s	797	0.0
GSEQ:AAH45082 Human SLC coding sequence.	797	0.0
GSEQ:AAC87018 Nucleotide sequence of human polypeptide PRO160	797	0.0
GSEQ:AAA47495 Human secondary lymphoid chemokine (SLC) coding	797	0.0
GSEQ:AAA53595 Human chemokine L105_3 cDNA.	797	0.0
GSEQ:AAV83754 cDNA encoding a human L105 chemokine designated	797	0.0
GSEQ:AAV41199 Nucleic acid encoding CC-type chemokine protein	797	0.0
GSEQ:AAT18015 Chemokine beta-9 coding sequence.	797	0.0
GSEQ:AAT33528 Pancreas expressed chemokine-2 gene.	797	0.0
GSEQ:AAC03779 Human secreted protein 5' EST, SEQ ID NO: 3777.	789	0.0
GSEQ:AAV07114 Nucleotide sequence of human 6CKine gene.	789	0.0
GSEQ:AAV41149 Human secreted protein 5' EST SEQ ID NO:93.	763	0.0
GSEQ:AAA53594 Human chemokine L105_7 cDNA.	735	0.0
GSEQ:AAV83755 cDNA encoding a human L105 chemokine designated	735	0.0
GSEQ:AAA53597 Human chemokine L105 cDNA homologue (EST W17274	731	0.0
GSEQ:AAV83758 EST W17274 homologous to a human L105 chemokine	731	0.0
GSEQ:AAA44595 Human secreted expressed sequence tag SEQ ID NO	555	e-156
GSEQ:AAK54697 Human haematological malignancy-related antigen	505	e-141

>GSEQ:AAT33528 Pancreas expressed chemokine-2 gene.
Length = 402

Score = 797 bits (402), Expect = 0.0
Identities = 402/402 (100%)
Strand = Plus / Plus

```
Query: 1  atggctcagtcactggctctgagcctccttatcctggttctggcctttggcatccccagg 60
          |||
Sbjct: 1  atggctcagtcactggctctgagcctccttatcctggttctggcctttggcatccccagg 60

Query: 61  acccaaggcagtgatggaggggctcaggactgttgccctcaagtacagccaaaggaagatt 120
          |||
Sbjct: 61  acccaaggcagtgatggaggggctcaggactgttgccctcaagtacagccaaaggaagatt 120

Query: 121 cccgccaaaggttgccgcagctaccggaagcaggaaccaagcttaggctgctccatccca 180
          |||
Sbjct: 121 cccgccaaaggttgccgcagctaccggaagcaggaaccaagcttaggctgctccatccca 180
```

Query: 181 gctatcctgtttcttgccccgcaagcgctctcaggcagagctatgtgcagacccaaaggag 240
|||||
Sbjct: 181 gctatcctgtttcttgccccgcaagcgctctcaggcagagctatgtgcagacccaaaggag 240

Query: 241 ctctgggtgcagcagctgatgcagcatctggacaagacaccatccccacagaaaccagcc 300
|||||
Sbjct: 241 ctctgggtgcagcagctgatgcagcatctggacaagacaccatccccacagaaaccagcc 300

Query: 301 cagggctgcaggaaggacaggggggcctccaagactggcaagaaaggaaagggtccaaa 360
|||||
Sbjct: 301 cagggctgcaggaaggacaggggggcctccaagactggcaagaaaggaaagggtccaaa 360

Query: 361 ggctgcaagaggactgagcggtcacagaccctaaagggcc 402
|||||
Sbjct: 361 ggctgcaagaggactgagcggtcacagaccctaaagggcc 402

Database: Geneseq.NA.2002AUG30

Posted date: Sep 4, 2002 11:15 AM

Number of letters in database: 1,057,821,503

Number of sequences in database: 2,085,897

Lambda	K	H
1.37	0.711	1.31

Gapped

Lambda	K	H
1.37	0.711	1.31

Matrix: blastn matrix:1 -3

Gap Penalties: Existence: 5, Extension: 2

Number of Hits to DB: 251332

Number of Sequences: 2085897

Number of extensions: 251332

Number of successful extensions: 70613

Number of sequences better than 10.0: 88

length of query: 402

length of database: 1,057,821,503

effective HSP length: 20

effective length of query: 382

effective length of database: 1,016,103,563

effective search space: 388151561066

effective search space used: 388151561066

T: 0

A: 0

X1: 6 (11.9 bits)

X2: 10 (19.8 bits)

S1: 12 (24.3 bits)

ID AAW00668
 CS 1e5b84dd1e9415153ea5cccla5806185
 IDH AAW00668 standard; Protein; 134 AA.
 MO PRT
 DV PRT
 DT1 02-MAY-1997 (first entry)
 DT 02-MAY-1997
AK PATENT WO9625497-A1
 AK PRIMARY AC AAW00668
 EAK
 DR N-PSDB AAT33528
 DR WPI 1996-393398/39
 EDR
 DE Pancreas expressed chemokine-2.
 KW PANEC-1
 KW PANEC-2
 KW Pancreas-derived chemokine
 KW cancer
 KW diagnosis
 KW disease
 KW inflammation
 EKW
 OS Homo sapiens.
 SC 4a22b9fcfbf65eca55a08e9eb4312eae
 SP HOMO SAPIENS
 ESP
 INST (INCY-) INCYTE PHARM INC
 CC The sequences given in AAW00667-68 represent pancreas-derived
 CC chemokines, PANEC-1 and PANEC-2. These chemokines are highly expressed
 CC and specifically expressed in the pancreas and may therefore be used in
 CC diagnostic assays based on chemokine production in cases of
 CC inflammation or disease affecting the pancreas. These assays allow
 CC the early and accurate diagnosis of pancreatic disorders, and can
 CC differentiate between invasive diseases and genetic syndromes.
 ECC
 RN 1 5blafd4fd0c84cblbd9ae4a901celdc9
 RC **PD: 22-AUG-1996. PF: 16-FEB-1996; 96WO-US02225. PR: 17-FEB-1995; 95US-0390740.**
 RT Nucleotide and protein sequences for human PANEC-1 and PANEC-2 - useful
 in diagnosis and therapy of pancreatic diseases
 RL Patent: WO9625497-A1. Claim 20; Page 30; 43pp; English.
 RA Bandman O. BANDMAN O
 RA Coleman R. COLEMAN R
 RA Wilde C.G. WILDE CG
 ERN
 SQH Sequence 134 AA;
 SL 134 68ed1c823cd8cd6dfa8558e496ccbea3
 SQ maqslalsllilvlafgiprtqgsdggagdcclksqrkipakvvrsyrkqepslgcsip
 SQ ailflprkrsqaclcadpkelwvqqmlmqhldktpspqkpaqgcrkdrqasktgkkgkgs
 SQ gckrtersqtpkpgp
 ESQ

NCBI-BLASTP 2.0.10 [Aug-26-1999]

Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

Query= PF-0027US_SEQ ID NO:4_PANEC-2_226152
(134 letters)

Database: Geneseq.AA.2002AUG30
887,419 sequences; 130,709,309 total letters

Searching.....done

Sequences producing significant alignments:	Score (bits)	E Value
GSEQ:ABG60666 Small inducible cytokine subfamily A member 21	278	1e-74
GSEQ:ABB95552 Human angiogenesis related protein PRO1600 SEQ	278	1e-74
GSEQ:ABB84946 Human PRO1600 protein sequence SEQ ID NO:260.	278	1e-74
GSEQ:AAB99213 Human SLC-interleukin-2 fusion protein #2.	278	1e-74
GSEQ:AAB99208 Human SLC-interleukin-2 fusion protein #1.	278	1e-74
GSEQ:AAB99206 Human SLC.	278	1e-74
GSEQ:AAB50860 Human CKbeta-9.	278	1e-74
GSEQ:AAB31199 Amino acid sequence of human polypeptide PRO160	278	1e-74
GSEQ:AAB01434 Human secondary lymphoid chemokine (SLC).	278	1e-74
GSEQ:AA96923 Human chemokine L105_3.	278	1e-74
GSEQ:AAW87588 A human L105 chemokine designated huL105_3.	278	1e-74
GSEQ:AAW50885 Amino acid sequence of human 6CKine protein.	278	1e-74
GSEQ:AAW69163 CC-type chemokine protein designated SLC.	278	1e-74
GSEQ:AAW00668 Pancreas expressed chemokine-2.	278	1e-74
GSEQ:AAG03773 Human secreted protein, SEQ ID NO: 7854.	276	4e-74
GSEQ:AAR81567 Chemokine beta-9.	274	1e-73
GSEQ:AA96922 Human chemokine L105_7.	269	5e-72
GSEQ:AAW87589 A human L105 chemokine designated huL105_7.	269	5e-72
GSEQ:AA912316 Human 5' EST secreted protein SEQ ID NO:347.	266	4e-71
GSEQ:AAO20021 Human chemokine SLC protein.	236	3e-62
GSEQ:AAO14154 Human SLC protein.	236	3e-62
GSEQ:AAB99211 Murine SLC-interleukin-2 fusion protein.	201	2e-51

>GSEQ:AAW00668 Pancreas expressed chemokine-2.
Length = 134

Score = 278 bits (703), Expect = 1e-74
Identities = 134/134 (100%), Positives = 134/134 (100%)

Query: 1 MAQSLALSLLILVLAFGIPRTQGS DGG AQDCCLKYSQRKIPAKVVR SYRKQEPSLGCSIP 60
MAQSLALSLLILVLAFGIPRTQGS DGG AQDCCLKYSQRKIPAKVVR SYRKQEPSLGCSIP
Sbjct: 1 MAQSLALSLLILVLAFGIPRTQGS DGG AQDCCLKYSQRKIPAKVVR SYRKQEPSLGCSIP 60

Query: 61 AILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSK 120
AILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSK
Sbjct: 61 AILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSK 120

Query: 121 GCKRTERSQTPKGP 134
GCKRTERSQTPKGP
Sbjct: 121 GCKRTERSQTPKGP 134

Database: Geneseq.AA.2002AUG30
Posted date: Sep 4, 2002 9:25 AM
Number of letters in database: 130,709,309
Number of sequences in database: 887,419

Lambda	K	H
0.316	0.133	0.400

Gapped Lambda	K	H
0.270	0.0470	0.230

Matrix: BLOSUM62
Gap Penalties: Existence: 11, Extension: 1
Number of Hits to DB: 37722616
Number of Sequences: 887419
Number of extensions: 1508406
Number of successful extensions: 6373
Number of sequences better than 10.0: 1105
Number of HSP's better than 10.0 without gapping: 438
Number of HSP's successfully gapped in prelim test: 667
Number of HSP's that attempted gapping in prelim test: 5016
Number of HSP's gapped (non-prelim): 1156
length of query: 134
length of database: 130,709,309
effective HSP length: 51
effective length of query: 83
effective length of database: 85,450,940
effective search space: 7092428020
effective search space used: 7092428020
T: 11
A: 40
X1: 16 (7.3 bits)
X2: 38 (14.8 bits)
X3: 64 (24.9 bits)
S1: 41 (21.6 bits)

ID **AAT33527**
CS 6d49469b240541ea3ab999d83dcc8b55
IDH AAT33527 standard; cDNA; 291 BP.
MO DNA
DV DNA
DT1 02-MAY-1997 (first entry)
DT 02-MAY-1997
AK **PATENT** **WO9625497-A1**
AK PRIMARY AC AAT33527
EAK
DR P-PSDB AAW00667
DR WPI 1996-393398/39
EDR
DE Pancreas expressed chemokine-1 gene.
KW PANEC-1
KW PANEC-2
KW Pancreas-derived chemokine
KW cancer
KW diagnosis
KW disease
KW inflammation
KW ss
EKW
OS Homo sapiens.
SC 4a22b9fcfbf65eca55a08e9eb4312eae
SP HOMO SAPIENS
ESP
INST (INCY-) INCYTE PHARM INC
CC The sequences given in AAT33527-28 encode pancreas-derived chemokines,
CC PANEC-1 and PANEC-2. These chemokines are highly expressed and
CC specifically expressed in the pancreas and may therefore be used in
CC diagnostic assays based on chemokine production in cases of
CC inflammation or disease affecting the pancreas. These assays allow
CC the early and accurate diagnosis of pancreatic disorders, and can
CC differentiate between invasive diseases and genetic syndromes.
ECC
RN 1 461eb35d3052fdc4b50fe9375d9a07d1
RC **PD: 22-AUG-1996. PF: 16-FEB-1996; 96WO-US02225. PR: 17-FEB-1995; 95US-**
0390740.
RT Nucleotide and protein sequences for human PANEC-1 and PANEC-2 - useful
in diagnosis and therapy of pancreatic diseases
RL Patent: WO9625497-A1. Claim 1; Page 28; 43pp; English.
RA Bandman O. BANDMAN O
RA Coleman R. COLEMAN R
RA Wilde C.G. WILDE CG
ERN
FK prim_transcript
LOC 1..289
LO 1 P 289 P 1 289 +
FQ note
FQ tag
QD a
NT Claimed sequence
EFK
SQH Sequence 291 BP; 79 A; 87 C; 68 G; 57 T; 0 other;
SL 291 0e9675461f0aac2aa21cc876ac357b4c
SQ atgaagggtctccgcagcacttctgtggctgctgctcatagcagctgccttcagccccag
SQ gggctcactgggccagcttctgtcccaaccacctgctgctttaacctggccaataggaag
SQ atacccttcagcgactagagagctacaggagaatcaccagtggcaaatgtccccagaaa
SQ gctgtgatcttcaagacaaaactggccaaggatatctgtgccgacccaagaagaagtgg
SQ gtgcaggattccatgaagtatctggacaaaaatctccaactccaaagcca
ESQ

ID **AAT58777**
 CS 0fb6fb2cfb87ece667365dfaa682935f
 IDH AAT58777 standard; cDNA; 294 BP.
 MO DNA
 DV DNA
 DT1 30-SEP-1997 (first entry)
 DT 30-SEP-1997
AK **PATENT** **WO9700960-A1**
 AK PRIMARY AC AAT58777
 EAK
 DR P-PSDB AAW10099
 DR WPI 1997-087387/08
 EDR
 DE Human eotaxin cDNA.
 KW AIDS
 KW Bechet's
 KW Crohn's
 KW Human
 KW ILD
 KW Loeffler's
 KW SLE
 KW Sjorgen's
 KW accumulation
 KW allergy
 KW allograft
 KW anaphylaxis
 KW ankylosing spondylitis
 KW asthma
 KW atherosclerosis
 KW atopic
 KW attraction
 KW autoimmune
 KW bowel
 KW cancer
 KW cephalosporin
 KW chemoattractant
 KW chemotaxis
 KW chemotherapy
 KW corticosteroid
 KW cutaneous
 KW dermatitis
 KW dermatomyositis
 KW dermatosis
 KW diagnosis
 KW disease
 KW drug
 KW ds
 KW eczema
 KW endotoxic
 KW eosinophil
 KW eotaxin
 KW fascitis
 KW glomerulonephritis
 KW graft
 KW graft versus host
 KW haematologic malignancy
 KW hypersensitivity
 KW idiopathic pulmonary fibrosis
 KW immunodeficiency
 KW immunosuppression
 KW infection
 KW inflammation
 KW insect sting
 KW interstitial

ID AAT58777 Contd.

KW juvenile onset diabetes
KW leukocyte infiltration
KW lung
KW lupus erythematosus
KW multiple sclerosis
KW myasthenia gravis
KW myositis
KW necrotising
KW penicillin
KW pneumonia
KW polymyositis
KW prevention
KW psoriasis
KW radiation therapy
KW rejection
KW reperfusion injury
KW rheumatoid arthritis
KW rhinitis
KW scleroderma
KW sclerosis
KW septic
KW shock
KW spondyloarthropathy
KW stimulation
KW syndrome
KW systemic
KW thyroiditis
KW transplantation
KW treatment
KW ulcerative colitis
KW urticaria
KW vasculitis

EKW

OS Homo sapiens.

SC 4a22b9fcfbf65eca55a08e9eb4312eae

SP HOMO SAPIENS

ESP

INST (LEUK-) LEUKOSITE INC

CC The present sequence encodes human eotaxin (hE), an eosinophil
CC specific chemoattractant capable of stimulating eosinophil
CC accumulation and/or attracting eosinophils (including chemotaxis).
CC It can be used to develop products for the diagnosis, prevention or
CC treatment of hE associated diseases or conditions. The products can
CC be used to treat inflammatory or allergic diseases and conditions,
CC including respiratory allergic diseases (e.g. asthma, allergic
CC rhinitis, hypersensitivity lung diseases or pneumonitis,
CC eosinophilic pneumonias such as Loeffler's syndrome and chronic
CC eosinophilic pneumonia, interstitial lung diseases (ILD) such as
CC idiopathic pulmonary fibrosis or ILD associated with rheumatoid
CC arthritis, systemic lupus erythematosus (SLE), ankylosing
CC spondylitis, systemic sclerosis, Sjorgen's syndrome, polymyositis
CC or dermatomyositis), systemic anaphylaxis or hypersensitivity
CC responses, drug allergies (e.g. to penicillin and cephalosporins),
CC insect sting allergies, inflammatory bowel diseases (e.g. Crohn's
CC disease and ulcerative colitis), spondyloarthropathies,
CC scleroderma, psoriasis and inflammatory dermatoses (e.g.
CC dermatitis, eczema, atopic dermatitis, allergic contact dermatitis,
CC urticaria and necrotising, cutaneous and hypersensitivity
CC vasculitis), eosinophilic myositis and fascitis, multiple
CC sclerosis, SLE, myasthenia gravis, juvenile onset diabetes,
CC glomerulonephritis, autoimmune thyroiditis, Bechet's disease, graft
CC rejection (e.g. in transplantation) including allograft rejection or

ID AAT58777 Contd.

CC graft versus host disease and cancers with leukocyte infiltration
CC of the skin or organs. The products can also be used to treat other
CC diseases or conditions requiring the inhibition of undesirable
CC inflammatory responses, including reperfusion injury,
CC atherosclerosis, certain haematologic malignancies, cytokine
CC induced toxicity (e.g. septic or endotoxic shock), polymyositis,
CC dermatomyositis, immunosuppression (e.g. in individuals with
CC immunodeficiency syndromes such as AIDS, undergoing radiation
CC therapy, chemotherapy, therapy for autoimmune disease or other drug
CC therapy, such as corticosteroid therapy, which causes
CC immunosuppression), immunosuppression due to (e.g. congenital)
CC deficiency (e.g. in eotaxin) or infectious diseases such as parasitic
CC diseases.

CC Degenerate primers based on the guinea pig eotaxin amino acid
CC sequence were used for the reverse transcriptase polymerase chain
CC reaction (RT-PCR) amplification of RNA isolated from inflamed,
CC eosinophilic lung tissue obtained from Balb/c mice sensitised to
CC ovalbumin. The amplification product was used as a probe to screen
CC a human genomic library in vector EMBL3 SP6/T7 to obtain the hE
CC gene.

ECC

RN 1 990670a0ea365953bb15937a3786975e

RC PD: 09-JAN-1997. PF: 21-JUN-1996; 96WO-US10723. PR: 23-JUN-1995; 95US-
0494093.

RT New isolated human eotaxin gene - used to develop prods. for the
diagnosis and treatment of e.g. inflammation, allergies, auto-immune disease,
infections and tumours

RL Patent: WO9700960-A1. Claim 6; Pages 95-96; 130pp; English.

RA MacKay C. MACKAY C

RA Newman W. NEWMAN W

RA Ponath P.D. PONATH PD

RA Qin S. QIN S

RA Ringler D.J. RINGLER DJ

ERN

FK CDS

LOC 1..294

LO 1 P 294 P 1 294 +

FQ product

QD eotaxin

FQ tag

QD a

EFK

SQH Sequence 294 BP; 80 A; 87 C; 69 G; 58 T; 0 other;

SL 294 545fc704ddf51ede4ffc45064a59b5e7

SQ atgaagggtctccgcagcacttctgtggctgctgctcatagcagctgccttcagccccag

SQ gggctcgcgtgggccagcttctgtcccaaccactgctgctttaacctggccaataggaag

SQ atacccttcagcgactagagagctacaggagaatcaccagtggcaaatgtccccagaaa

SQ gctgtgatcttcaagaccaaactggccaaggatatctgtgccgacccaagaagaagtgg

SQ gtgcaggattccatgaagtatctggacaaaaatctccaactccaaagccataa

ESQ

ID AAW00667
CS 73b865eb565b944785515de9c62072b9
IDH AAW00667 standard; Protein; 97 AA.
MO PRT
DV PRT
DT1 02-MAY-1997 (first entry)
DT 02-MAY-1997
AK **PATENT WO9625497-A1**
AK PRIMARY AC AAW00667
EAK
DR N-PSDB AAT33527
DR WPI 1996-393398/39
EDR
DE Pancreas expressed chemokine-1.
KW PANEC-1
KW PANEC-2
KW Pancreas-derived chemokine
KW cancer
KW diagnosis
KW disease
KW inflammation
EKW
OS Homo sapiens.
SC 4a22b9fcfbf65eca55a08e9eb4312eac
SP HOMO SAPIENS
ESP
INST (INCY-) INCYTE PHARM INC
CC The sequences given in AAW00667-68 represent pancreas-derived
CC chemokines, PANEC-1 and PANEC-2. These chemokines are highly expressed
CC and specifically expressed in the pancreas and may therefore be used in
CC diagnostic assays based on chemokine production in cases of
CC inflammation or disease affecting the pancreas. These assays allow
CC the early and accurate diagnosis of pancreatic disorders, and can
CC differentiate between invasive diseases and genetic syndromes.
ECC
RN 1 b7fe513084a4890bb092b778596fdf18
RC **PD: 22-AUG-1996. PF: 16-FEB-1996; 96WO-US02225. PR: 17-FEB-1995; 95US-0390740.**
RT Nucleotide and protein sequences for human PANEC-1 and PANEC-2 - useful in diagnosis and therapy of
pancreatic diseases.
RL Patent: WO9625497-A1. Claim 8; Page 28-29; 43pp; English.
RA Bandman O. BANDMAN O
RA Coleman R. COLEMAN R
RA Wilde C.G. WILDE CG
ERN
SQH Sequence 97 AA;
SL 97 7a45cdbbdfd2a7f29f68b9210811e148
SQ mkvsaallwilliaafspqgltpasvptccfnlanrkiplqrlesyrritsgkcpqk
SQ avifktklakdicadpkkkwwqdsdkyldqksptpkp
ESQ

Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

Query= PF-0027US_SEQ ID NO:2_228187
(97 letters)

Database: Geneseq.AA.2002AUG30
887,419 sequences; 130,709,309 total letters

Searching.....done

Sequences producing significant alignments:	Score (bits)	E Value
GSEQ:AAW00667 Pancreas expressed chemokine-1.	203	3e-52
GSEQ:AAW10099 Human eotaxin.	201	1e-51
GSEQ:AAW14990 Human eosinocyte CC type chemokine eotaxin.	201	1e-51
GSEQ:AAW44721 Amino acid sequence of the secreted protein enc	167	1e-41

> **GSEQ:AAW00667** Pancreas expressed chemokine-1.
Length = 97

Score = 203 bits (510), Expect = 3e-52
Identities = 97/97 (100%), Positives = 97/97 (100%)

Query: 1 MKVSAALLWLLLIAAAFSPQGLTGPASVPTTCCFNLANRKIPLQRLESYRRITSGKCPQK 60
MKVSAALLWLLLIAAAFSPQGLTGPASVPTTCCFNLANRKIPLQRLESYRRITSGKCPQK
Sbjct: 1 MKVSAALLWLLLIAAAFSPQGLTGPASVPTTCCFNLANRKIPLQRLESYRRITSGKCPQK 60

Query: 61 AVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP 97
AVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP
Sbjct: 61 AVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP 97

GSEQ:AAW00667 Contd.

Database: Geneseq.AA.2002AUG30

Posted date: Sep 4, 2002 9:25 AM

Number of letters in database: 130,709,309

Number of sequences in database: 887,419

Lambda	K	H
0.320	0.133	0.413

Gapped

Lambda	K	H
0.270	0.0470	0.230

Matrix: BLOSUM62

Gap Penalties: Existence: 11, Extension: 1

Number of Hits to DB: 27383911

Number of Sequences: 887419

Number of extensions: 920834

Number of successful extensions: 3814

Number of sequences better than 10.0: 1205

Number of HSP's better than 10.0 without gapping: 1120

Number of HSP's successfully gapped in prelim test: 85

Number of HSP's that attempted gapping in prelim test: 2081

Number of HSP's gapped (non-prelim): 1205

length of query: 97

length of database: 130,709,309

effective HSP length: 48

effective length of query: 49

effective length of database: 88,113,197

effective search space: 4317546653

effective search space used: 4317546653

T: 11

A: 40

X1: 16 (7.4 bits)

X2: 38 (14.8 bits)

X3: 64 (24.9 bits)

S1: 41 (21.8 bits)

NCBI-BLASTN 2.0.10 [Aug-26-1999]

Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

Query= PF-0027US_SEQ ID NO:1_228187
(291 letters)

Database: Geneseq.NA.2002AUG30
2,085,897 sequences; 1,057,821,503 total letters

Searching.....done

Sequences producing significant alignments:	Score (bits)	E Value
GSEQ:AAT33527 Pancreas expressed chemokine-1 gene.	577	e-163
GSEQ:AAT58777 Human eotaxin cDNA.	569	e-160
GSEQ:AAT62944 Human eosinocyte CC type chemokine eotaxin cDNA	569	e-160
GSEQ:AAV05729 Nucleotide sequence of clone AM262_11.	547	e-154

>**GSEQ:AAT33527** Pancreas expressed chemokine-1 gene.
Length = 291

Score = 577 bits (291), Expect = e-163
Identities = 291/291 (100%)
Strand = Plus / Plus

```
Query: 1   atgaaggtctccgcagcacttctgtggctgctgctcatagcagctgccttcagccccag 60
          |||
Sbjct: 1   atgaaggtctccgcagcacttctgtggctgctgctcatagcagctgccttcagccccag 60

Query: 61   gggctcactgggccagcttctgtcccaaccacctgctgctttaacctggccaataggaag 120
          |||
Sbjct: 61   gggctcactgggccagcttctgtcccaaccacctgctgctttaacctggccaataggaag 120

Query: 121  atacccttcagcgactagagagctacaggagaatcaccagtggcaaagtgtccccagaaa 180
          |||
Sbjct: 121  atacccttcagcgactagagagctacaggagaatcaccagtggcaaagtgtccccagaaa 180

Query: 181  gctgtgatcttcaagaccaaactggccaaggatatctgtgccgaccccaagaagaagtgg 240
          |||
Sbjct: 181  gctgtgatcttcaagaccaaactggccaaggatatctgtgccgaccccaagaagaagtgg 240

Query: 241  gtgcaggattccatgaagtatctggacaaaaatctccaactccaaagcca 291
          |||
Sbjct: 241  gtgcaggattccatgaagtatctggacaaaaatctccaactccaaagcca 291
```

GSEQ:AAT33527 Contd.

Database: Geneseq.NA.2002AUG30

Posted date: Sep 4, 2002 11:15 AM

Number of letters in database: 1,057,821,503

Number of sequences in database: 2,085,897

Lambda	K	H
1.37	0.711	1.31

Gapped

Lambda	K	H
1.37	0.711	1.31

Matrix: blastn matrix:1 -3

Gap Penalties: Existence: 5, Extension: 2

Number of Hits to DB: 210948

Number of Sequences: 2085897

Number of extensions: 210948

Number of successful extensions: 65457

Number of sequences better than 10.0: 201

length of query: 291

length of database: 1,057,821,503

effective HSP length: 19

effective length of query: 272

effective length of database: 1,018,189,460

effective search space: 276947533120

effective search space used: 276947533120

T: 0

A: 0

X1: 6 (11.9 bits)

X2: 10 (19.8 bits)

S1: 12 (24.3 bits)